Citadel Advisors
NAVB

Citadel Advisors’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Citadel Advisors’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,400
Closed -$624 – 15790
2023
Q1 		$624 Sell
2,400
-7,700
-76% -$2.25K ﹤0.01% 14452
2022
Q4 		$2.12K Sell
10,100
-24,000
-70% -$6K ﹤0.01% 14378
2022
Q3 		$9K Buy
34,100
+7,900
+30% +$3.69K ﹤0.01% 12307
2022
Q2 		$19K Buy
26,200
+11,500
+78% +$9.77K ﹤0.01% 12435
2022
Q1 		$12K Buy
14,700
+4,000
+37% +$3.67K ﹤0.01% 13370
2021
Q4 		$11K Sell
10,700
-6,500
-38% -$9.15K ﹤0.01% 13667
2021
Q3 		$30K Sell
17,200
-22,900
-57% -$38.5K ﹤0.01% 13577
2021
Q2 		$73K Buy
40,100
+7,200
+22% +$12.7K ﹤0.01% 13140
2021
Q1 		$66K Buy
32,900
+12,200
+59% +$28.6K ﹤0.01% 12775
2020
Q4 		$45K Buy
+20,700
New +$48.8K ﹤0.01% 10608
2020
Q3 		– Sell
-14,000
Closed -$55K – 11195
2020
Q2 		$55K Buy
+14,000
New +$26.8K ﹤0.01% 9262
2019
Q2 		– Sell
-525
Closed -$1K – 10331
2019
Q1 		$1K Buy
+525
New +$1.55K ﹤0.01% 9185
2016
Q1 		– Sell
-205
Closed -$5K – 8610
2015
Q4 		$5K Sell
205
-635
-76% -$22.1K ﹤0.01% 8464
2015
Q3 		$38K Buy
+840
New +$31.7K ﹤0.01% 7775
2015
Q1 		– Sell
-500
Closed -$19K – 9012
2014
Q4 		$19K Buy
500
+420
+525% +$11.6K ﹤0.01% 7864
2014
Q3 		$2K Sell
80
-865
-92% -$22.9K ﹤0.01% 8009
2014
Q2 		$28K Buy
945
+505
+115% +$16.3K ﹤0.01% 7124
2014
Q1 		$16K Sell
440
-125
-22% -$4.74K ﹤0.01% 7376
2013
Q4 		$23K Buy
565
+70
+14% +$2.74K ﹤0.01% 6395
2013
Q3 		$26K Sell
495
-5
-1% -$291 ﹤0.01% 6102
2013
Q2 		$27K Buy
+500
New +$25K ﹤0.01% 5943

Other funds holding NAVB

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PFO
Pathstone Family Office Englewood, New Jersey $13.1B AUM 21.02% 1-Year Est. Return

Citadel Advisors's NAVB Position: Q2 2023 in Review

Citadel Advisors sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2023, closing a stake of 65,807 shares — an estimated $17.1K sold.

Citadel Advisors first reported a position in NAVB in Q2 2013 and held it in 35 quarters. The position peaked at $178K in Q4 2014. 23 funds tracked by Wall St. Rank hold NAVB as of Q2 2023.

  • Citadel Advisors reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2023 after selling out during the quarter.
  • Citadel Advisors sold 65,807 Navidea Biopharmaceuticals Inc. shares in Q2 2023, an estimated $17.1K.
  • Citadel Advisors first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 35 quarters.
  • Citadel Advisors's Navidea Biopharmaceuticals Inc. position peaked at $178K in Q4 2014.
  • 23 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.